UESC Immunohistochemistry data
 
SCGAP Consortium
   Portal
NIH/NIDDK Main
ISB Main
SBEAMS login
Project Information
Project Home
Project Aims
Contacts
Publications
Feedback Form
Search site
Data Access
Immunostain Database
Microarray Database
Cytometry Database
Data Summary
Bulk Data Loading
Anatomy & Ontology
Glossary
Anatomy
Data Standards
MAGE/MIAME
MISFISHIE
Resources
Protocols
Prostate CD Specificity
Luminal & basal cells
   in PEDB
CD Resources (PROW)
PEDB
Software Links
 

Human expression data summary

This document presents our data in a MISFISHIE-compliant manner. You can download all of the data tables in this page individually, or all together as a zip archive of TSV or CSV files. You can also download a zip archive of all the human IHC images ( 589 MB).

Experimental Design:

  • Experiment Description: An immunohistochemical comparison of various anti-CD antibodies in many different human bladder and prostate tissue sections.
  • Assay Type: Immunohistochemistry
  • Experiment Type: Comparison of multiple tissue specimens and antibodies
  • Experimental factors: antibody; specimen; organism (human)
  • The number of hybridizations/stains performed in the experiment: 687
  • URL of any supplemental websites or database accession numbers related to the experiment: http://scgap.systemsbiology.org/data/
  • Contact information for communicating with the experimenter(s): Eric Deutsch, Institute for Systems Biology, 1441 N 34th St, Seattle WA 98103 (edeutsch systemsbiology.org)

Specimens (BioMaterials) used, section or mount preparation (Treatment):

  • The origin of the biological specimens (e.g., name of the organism, the provider of the specimen) and their characteristics: e.g., sex, developmental stage, age, strain, genotype, phenotype, disease state, treatments, etc. All information critical for other researchers to be able to reproduce the biomaterials as closely as possible must be provided (not limited to the above examples). Referencing an established ontology for the terms you use is HIGHLY encouraged. All specimens were obtained from the University of Washington Medical Center.
  • Manipulation of specimens into sections (or preparation for mounting if whole mounts), and the protocols used: Specimen Preparation Protocol

    Specimen Designator Tissue Type Organism Gender
    99-111 Bladder Homo sapiens Unknown
    00-042 Bladder Homo sapiens Unknown
    01-0174 Bladder Homo sapiens Unknown
    02-017 Bladder Homo sapiens Unknown
    02-067 Bladder Homo sapiens Unknown
    02-156 Bladder Homo sapiens Unknown
    02-156B3 Bladder Homo sapiens Unknown
    02-160 Bladder Homo sapiens Unknown
    02-160B1 Bladder Homo sapiens Unknown
    02-215 Bladder Homo sapiens Unknown
    View All Rows   Export as: TSV CSV

Probe or antibody information:

  • Unambiguous genomic identification of the probe or antibody:
  • At minimum, the gene identifier and the reference database containing the identifier
  • If available, the full sequence of the probe, or clone identifiers of the antibody.
  • Protocol for how the probes or antibodies were designed and produced or the source from which they were obtained. For GFP experiments, the promoter sequence should be specified as the "probe".
  • For probes or antibodies purchased from a company, the company name and catalog number must be provided, as well as the web site which details the specifications if available.
  • For a custom made antibody the putative antigen and references to studies that characterize the sensitivity and specificity of the antibody in tissue immunostains should be provided. Virtually all monoclonal antibodies purchased from BD Pharmingen

    Ab Name Ref Db Accession Origin Vendor Details
    CD1a Locus Link 909 321 CD1a
    CD1b Locus Link 910 321 CD1b
    CD1c Locus Link 911 321 CD1c
    CD1d Locus Link 912 321 CD1d
    CD1e Locus Link 913 321 CD1e
    CD2 Locus Link 914 321 CD2
    CD3delta Locus Link 915 321 CD3delta
    CDe Locus Link 916 321 CDe
    CD3gamma Locus Link 917 321 CD3gamma
    CD4 Locus Link 920 321 CD4
    View All Rows   Export as: TSV CSV

Staining protocols and parameters:

  • Number of detectable probes or antibodies on the hybridization or stain. For most hybridizations/stains this will be one. If multiple hybridizations/stains are applied to a section, i.e. for confocal microscopy, the number will exceed one.

    View All Rows   Export as: TSV CSV

  • The protocol and conditions used to produce the hybridization or immunostain, including mounting onto the slide/substrate and subsequent treatments of the section, i.e. immunohistochemical stain protocol: Slide Preparation Protocol
  • Also provide protocols for the assay controls:

    Imaging data and parameters:

    • The images. Although the MIAME specification stops short of requiring image data, the present specification requires that images be provided since the interpretation of in situ or immunohistochemistry images is subject to observer variability. Furthermore, many specimens are unique; consequently, exact reproduction can be problematic or impossible. Include both positive and negative results.
    • Image acquisition parameters:
      • Detection method by which hybridization or staining is observed (for each channel {e.g. fluorescent wavelength, etc.} if multiple probes or antibodies are used): ????
      • Image scale or total instrumental magnification: See table below
      • Image acquisition protocol: SCGAP UESC Image Acquisition Protocol
      • Imaging hardware and software used: Olympus BX41, Adobe Photoshop 5
      • Image analysis and/or editing software used (if relevant): Adobe Photoshop 5

        View All Rows   Export as: TSV CSV

      Image Characterizations:

      The type of characterization that is recorded for such data can vary significantly depending on the experimental design. The following guidelines specify a minimum set of characterization features. Additional characterization of the images as required by the experimental design should also be provided. Include both positive and negative results.

      • List ontology entries (including reference to ontology, terms, accession numbers) (or provide term and definition if sufficient detail cannot be found in an existing ontology) for each structural unit used for classification. Structural units will be a type of: organ, tissue, cell, etc.

        See also: http://scgap.systemsbiology.net/ontology/Glossary.php
        View All Rows   Export as: TSV CSV

      • Define (or choose from an ontology) the staining intensity scale. For example, a three-point scale (of none, equivocal, or intense) is recommended for evaluating CD immunostains. Each gradation of intensity in the scale that is used should be properly defined.

            Export as: TSV CSV

      • For each structural unit in each slide (or, in each image), provide quantitative measurements or estimates of:
        • Staining intensity (as defined above)
        • Fraction of the structural unit population exhibiting that intensity. If the assay does not allow the detection of non-stained members of the structural unit population, it is permissable to denote that staining at the specified level of the structural unit is visible but the fraction of the total population is unknown.
        • Other optional annotations/characterizations of the structural unit, e.g., feature density, qualitative characteristics or spatial distribution of the structural unit. Use of referenced-ontology terms is encouraged.
        Note that there may well be many or mostly negative results in the resulting data, not just positive results. Lack of staining relevant to the experiment where it could have been seen should be reported.
        For example, 
        	Epithelial cell: 90% intense, 10% equivocal, 0% none
	Basal cell: 0% intense, 20% equivocal, 80% none
	etc.

        View All Rows   Export as: TSV CSV


    • SCGAP UESC - ISB / UW